Colorful, flowing light trails on a dark background, creating a dynamic and modern abstract design.

Accelerating Drug Repurposing Opportunities in Multiple Sclerosis Using AI

1 minute read

Published: July 9th, 2026

How can pharmaceutical companies uncover new value from existing therapies without the cost and risk of developing new drugs from scratch?

In this case study, discover how a leading pharmaceutical organization partnered with Phastar to apply AI and real-world evidence (RWE) to identify promising new indications for approved therapies in multiple sclerosis and related autoimmune diseases.

Using millions of longitudinal patient records across the US and Europe, the team developed a scalable, data-driven approach to drug repurposing that accelerated insight generation and supported better strategic decision-making.

Download the case study to learn how:

  • AI was used to identify new therapeutic opportunities at scale
  • Real-world data revealed previously unseen treatment outcomes
  • Discovery timelines were accelerated
  • Existing drug assets delivered greater value and commercial potential
  • Data-driven insights reduced development risk and improved confidence

Download the full case study, by completing the form below, to see how AI and biometrics expertise can help unlock new opportunities across your drug portfolio.

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...